Latest Breaking News On - கீந் தொழில்நுட்பங்கள் - Page 6 : comparemela.com
Global Lentiviral Vectors Market Insights, Overview, Analysis and Forecast 2021-2026
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
H6ST1 Antibody Market - Global Industry Analysis, By Key Players, Segmentation, Trends and Forecast By 2026
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The Global Biochip Market is expected to grow at an impressive rate of around 15% during the forecast period.
The Global Biochip Market is driven by the growing prevalence of various chronic and infectious disease especially in the geriatric population who are more susceptible to these diseases on account of low immunity. This has led to the increase in the demand for personalized medicine solutions or targeted therapies especially for treating diseases like cancer. This in turn is expected to positively influence the market growth over the next few years.
Additionally, increasing R&D activities and supportive government policies further propel the market. Furthermore, ongoing technological innovations and new product launches by the major players operating in the market is expected to create lucrative opportunities for market growth through 2026.
size is expected
to reach USD 7.9 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected
to expand at a CAGR of 15.1%
from 2021 to 2028. Technological advancements in viral vectors, a growing pipeline of advanced therapies, and a rising number of regulatory approvals for advance therapy products are some key driving forces of the market.
Key suggestions from the report:
The wide implementation of biological gene delivery technologies in clinical usage owing to their high efficiency and specificity has resulted in the segment s largest revenue share in 2020
Gene therapy development is the key revenue-generating application in the 2020 market owing to constantly expanding pipeline programs of therapies against life-threatening conditions coupled with the recent success of CAR-T therapies
01/18/2021 | Press release | Distributed by Public on 01/18/2021 12:19
Aruvant chooses Lonza to Manufacture ARU-1801, a Potentially curative Treatment for Sickle Cell Disease, for Pivotal Trial
Lonza to perform process development activities to establish a robust manufacturing process for ARU-1801, a potentially curative treatment for sickle cell disease
Lonza to provide cGMP material supply of ARU-1801 for its use in a pivotal clinical study in the United States
Quote from Palani Palaniappan, Chief Technology Officer, Aruvant Sciences: We are partnering with Lonza, one of the world s leading cell and gene therapy manufacturing organizations, to help us manufacture our gene therapy, ARU-1801, a potential cure for sickle cell disease that can be given with one low dose of chemotherapy. Our internal cell therapy process expertise combined with Lonza s cell processing know-how provide the perfect combination to manufacture ARU-1801 for our pivotal study. As we advanceour gene ther
vimarsana © 2020. All Rights Reserved.